Embleton M J, Byers V S, Lee H M, Scannon P, Blackhall N W, Baldwin R W
Cancer Res. 1986 Nov;46(11):5524-8.
Ricin toxin A chain (RTA) was conjugated to monoclonal antibody 791T/36, which was raised originally against human osteogenic sarcoma cell line 791T. The resultant conjugates were characterized and tested for cytotoxicity against a panel of human tumor cell lines representing a defined range of antigenicity with regard to 791T/36. Conjugates were highly cytotoxic for cells expressing high antigen density, inhibiting cell survival at RTA concentrations three to four orders of magnitude lower than that possible with RTA alone. Cytotoxicity of conjugates diminished with decreasing 791T/36 antigen concentration on target cells, but significant effects were seen against cells of low or intermediate antigenicity. Cytotoxicity could be blocked specifically by excess 791T/36 antibody, clearly indicating that antigen binding was a necessary part of the mechanism of action. Comparison with drug-antibody conjugates indicated that RTA immunotoxins are much more active, but discriminate less readily than drug-antibody conjugates between cells of different antigenicity. It is suggested that these properties be taken into account with regard to practical application and future development.
蓖麻毒素A链(RTA)与单克隆抗体791T/36偶联,该单克隆抗体最初是针对人骨肉瘤细胞系791T产生的。对所得偶联物进行了表征,并测试了其对一组人肿瘤细胞系的细胞毒性,这些细胞系在791T/36抗原性方面具有确定的范围。偶联物对表达高抗原密度的细胞具有高度细胞毒性,在RTA浓度比单独使用RTA时低三到四个数量级的情况下抑制细胞存活。随着靶细胞上791T/36抗原浓度的降低,偶联物的细胞毒性减弱,但对低或中等抗原性的细胞仍有显著作用。细胞毒性可被过量的791T/36抗体特异性阻断,这清楚地表明抗原结合是作用机制的必要组成部分。与药物-抗体偶联物的比较表明,RTA免疫毒素活性更高,但在不同抗原性的细胞之间比药物-抗体偶联物更不容易区分。建议在实际应用和未来发展中考虑这些特性。